November 18, 2011

Limiting Hepatitis C Virus Progression in Liver Transplant Recipients Using Sirolimus-Based Immunosuppression


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Hepatitis C recurrence following liver transplantation is universal, and it is one of the main reasons for inferior outcomes in this population. Sirolimus, which has antifibrotic properties, reduces progression of liver fibrosis in animal models. In this single-centre, retrospective study, liver transplant recipients initially treated with sirolimus showed less progression of fibrosis on surveillance biopsies than patients treated with other immunosuppressants. This represents the first study to show reduced progression of fibrosis in hepatitis C transplant recipients.

Liver Transplantation

Tags: , , , ,